- Lupin Manufacturing Solutions has expanded its Dabhasa manufacturing facility to scale peptide building-block capabilities and CRDMO services.
- The expansion adds new infrastructure and specialised units to support advanced development and flexible manufacturing.
Lupin Manufacturing Solutions has announced the expansion of its Dabhasa manufacturing facility to enhance its peptide building-block platform and contract research, development and manufacturing organisation (CRDMO) capabilities. The upgrade includes a new block and additional specialised units designed to support advanced development and flexible manufacturing.
The expansion introduces dedicated peptide manufacturing capacity across two additional units, enabling the company to support complex therapeutics and respond to global demand for advanced pharmaceutical solutions. The facility upgrade is intended to strengthen the company’s ability to deliver development and manufacturing services within its contract manufacturing operations.
The initiative comes as pharmaceutical development increasingly focuses on complex modalities, including peptides and biologic antibody-drug conjugates (ADCs). The company stated that the expanded infrastructure will support consistent supply of peptide building blocks, including protected amino acids.
“As pharmaceutical innovation increasingly shifts toward complex modalities, building deep capabilities and execution excellence has become critical.”
Dr Abdelaziz Toumi, Chief Executive Officer, Lupin Manufacturing Solutions
Lupin Manufacturing Solutions said the expansion is aimed at reinforcing its role within the global peptide ecosystem by enabling scalable capabilities and supporting partnerships with pharmaceutical innovators.
